PQQ Human Trials Explained: What Do Clinical Studies Show?

PQQ has an appealing story. It appears in discussions about memory, mental sharpness, cellular energy and healthy aging, often alongside impressive descriptions of mitochondrial biology. But an ingredient can behave one way in a laboratory and quite differently in a person going about an ordinary day. Before taking any supplement claim seriously, it helps to ask a more practical question: what happened when researchers gave PQQ to real people and measured the results against a control group?

Human studies have tested pyrroloquinoline quinone (PQQ), including randomized, double-blind, placebo-controlled trials. Small cognitive studies have reported improvements in certain memory, attention and processing measures after approximately 12 weeks at 20–21.5 mg daily. Other research has identified changes in mitochondrial-related biomarkers without corresponding gains in aerobic performance. These findings justify further research but do not establish broad, predictable benefits for everyday energy or long-term health.

The details are what make the research useful. One trial may find a difference in a computerized memory score, while another finds a change in a protein associated with mitochondrial regulation. Neither result automatically tells you whether you will feel more focused in meetings, recover faster from exercise or benefit from years of supplementation. The following review separates actual human findings from plausible mechanisms, explains the studied doses and safety limits, and shows how to judge a PQQ-containing product without turning early evidence into a promise.

What Do Human Trials Say About PQQ?

Human PQQ trials have reported favorable changes in selected cognitive measures and metabolic markers, although the findings are not uniform across outcomes. Several studies lasted 12 weeks and enrolled fewer than 100 participants, while early metabolism research followed very small groups for only days. These studies show that PQQ has been investigated in people, but they leave substantial uncertainty about practical benefits and reproducibility.

The first useful distinction is between whether an ingredient has been studied and whether a specific benefit has been established. PQQ has been tested in humans, so it would be inaccurate to call it purely an animal-research ingredient. Yet the number of participants and the range of outcomes are still limited compared with what would be needed to establish reliable effects for a broad population. Study design, age, ingredient form and follow-up duration all influence what each published paper can tell us.

Which PQQ Human Trials Have Been Published?

Several human investigations provide a reasonable starting point for understanding the evidence. Harris and colleagues examined short-term metabolic changes in 10 adults in 2013. Itoh and colleagues tested cognitive outcomes in 41 healthy older participants in a 2016 publication. Shiojima and colleagues later randomized 64 adults, of whom 58 completed a 12-week cognitive trial. A 2023 study by Tamakoshi and colleagues evaluated 62 adults of different ages, while Hwang and colleagues investigated exercise adaptation in 23 previously untrained men.

The studies did not ask precisely the same question. Memory tests, inflammation-related measurements, mitochondrial-associated proteins and exercise performance are different endpoints, so their findings should not be counted as five confirmations of a single broad benefit. The table below identifies the population, dose and main conclusion of each study without implying that the preparations or participants were interchangeable. It also helps distinguish evidence gathered under controlled trial conditions from conclusions that would require further testing.

Study	Participants	Dose and duration	Main observation
Harris et al., 2013	10 adults	0.2 mg/kg once; 0.3 mg/kg daily in a separate experiment, observed for 48–76 hours	Changes in selected inflammatory and urinary metabolic markers
Itoh et al., 2016	41 healthy older adults	20 mg/day for 12 weeks	Favorable findings in selected attention tests; some visuospatial results depended on subgroup
Hwang et al., 2020	23 untrained men	20 mg/day during 6 weeks of endurance training	Higher PGC-1α protein levels; no superior aerobic performance
Shiojima et al., 2022	64 randomized; 58 completed	21.5 mg/day for 12 weeks	Favorable differences in several computerized cognitive scores
Tamakoshi et al., 2023	62 adults, ages 20–65	20 mg/day for 12 weeks	Favorable memory findings, with different patterns in age subgroups

These reports are accessible through the original scientific record, including the 2013 metabolism study, 2016 cognitive study, 2020 exercise study, 2022 cognitive study and 2023 cognitive study. Their value lies in the specific questions they investigated, not in the length of the list. Anyone reviewing a scientific claim should begin with the original publication and check whether its participants, exposure and outcomes actually match the claim being made.

How Were the Clinical Trials Designed?

Several cognitive studies used randomized, double-blind, placebo-controlled methods. Random assignment helps distribute participant differences between groups, while blinding reduces the likelihood that expectations influence how participants behave or how researchers evaluate them. Placebo comparisons are especially important in cognitive testing because people can perform better simply by becoming familiar with the questions or testing software. A change from the beginning to the end of a study matters less than the difference between groups undergoing the same assessments.

For example, Shiojima's study randomized 64 participants, but 58 completed the intervention: 27 in the PQQ group and 31 in the placebo group. That completion figure is important because missing data can affect results in a modestly sized trial. Researchers should also account for baseline differences, specify their main outcome in advance and explain how they handle multiple statistical comparisons. Some PQQ studies include authors associated with ingredient companies; disclosed commercial involvement does not invalidate a study, but replication by independent researchers would make the conclusions more convincing.

What Outcomes Did Researchers Measure?

In cognitive trials, participants usually complete standardized tests rather than simply answer whether they feel sharper. The Cognitrax system assesses domains such as verbal memory, composite memory, reaction time, complex attention, processing speed and cognitive flexibility. Other studies used Stroop or reverse-Stroop tests to examine selective attention and interference control. These are established ways of describing aspects of cognitive performance, but a change in one domain should not be presented as proof that every aspect of memory or concentration has improved.

Metabolism and exercise studies ask different questions. Harris and colleagues measured blood markers, including C-reactive protein and interleukin-6, together with urinary metabolites. Hwang and colleagues examined PGC-1α, a protein associated with mitochondrial regulation, along with aerobic exercise measures. A biomarker tells researchers something about a physiological process; it does not necessarily show that participants felt better or functioned better. An especially strong study would demonstrate both a reliable biological change and a meaningful outcome that people could recognize in daily life.

How Do the Trial Results Compare?

The most encouraging human findings concern selected cognitive assessments, particularly in trials lasting 12 weeks. The 2016, 2022 and 2023 studies all reported favorable results in some measures of attention, memory or processing, but the tests and enrolled age groups were not the same. That makes it difficult to combine their results into one straightforward estimate of how much PQQ improves cognition, or even to predict which adults might notice any change outside a testing room.

Exercise results provide an important counterweight. In the 2020 Hwang study, PQQ participants showed a change in PGC-1α protein levels, yet their aerobic performance was not significantly better than placebo after training. This is not an inconsistency to hide; it is the difference between a measured molecular response and a demonstrated physical outcome. The combined research picture is neither empty nor conclusive. It supports carefully framed questions about PQQ while leaving broad promises about mental clarity, stamina and long-term wellness unproven.

Does PQQ Improve Memory and Focus?

Some randomized human trials have found improvements in selected memory, attention and processing measures after PQQ supplementation, often using 20–21.5 mg daily for 12 weeks. The results are scientifically interesting, particularly in certain age groups, but the trials have been relatively small. Better computerized test scores cannot automatically be translated into noticeably sharper thinking, dependable daily concentration or protection against cognitive decline.

Anyone who has tried to concentrate after a poor night's sleep knows that mental performance changes from day to day. Attention and memory are influenced by rest, stress, medications, hearing, physical activity and how comfortable someone feels with a task. Researchers try to control some of these variables, yet cognitive health remains more complicated than a single score. That makes it useful to examine the individual PQQ studies rather than reducing all their findings to a statement that the ingredient improves brain function.

What Did the 2022 Cognitive Trial Find?

Shiojima and colleagues studied a specified PQQ disodium salt preparation in healthy Japanese adults aged 40 to under 80. Participants were randomized to take 21.5 mg daily or placebo for 12 weeks. Of 64 enrolled participants, 58 completed the trial, and their average age at completion was approximately 71–72 years. The authors reported statistically significant differences favoring PQQ in several Cognitrax domains, including composite memory, verbal memory, reaction time, complex attention, cognitive flexibility, executive function and motor speed.

Questionnaires and additional screening assessments also produced favorable reported results, while no adverse events were observed during the trial. Those findings make the study relevant, but its sample size and older participant profile place limits on generalization. Most working-age adults do not have the same baseline characteristics as a group averaging over 70 years old. The result is better understood as evidence of selected cognitive-test changes in the studied population, not as confirmation that PQQ improves all aspects of memory in adults of every age.

What Did the 2023 Cognitive Trial Find?

Tamakoshi and colleagues examined 62 adults aged 20–65 who received either 20 mg of PQQ daily or placebo over 12 weeks. The investigators assessed cognition at baseline and again at eight and twelve weeks. Across the full participant group, the paper reported favorable differences in composite memory and verbal memory at 12 weeks. The authors also explored age-stratified results, making the trial particularly relevant to questions about whether younger and middle-aged adults respond in the same way.

Among adults aged 20–40, favorable findings appeared in cognitive flexibility, processing speed and executive speed at eight weeks. Participants aged 41–65 showed reported memory-related findings at twelve weeks. These differences are worth investigating but should not be treated as reliable timetables for personal results. When a study of 62 people is divided into smaller age groups, the estimates become less precise. The publication also reports a connection to an ingredient manufacturer, reinforcing the importance of independently repeating the research before drawing broad consumer conclusions.

Are Cognitive Benefits Different by Age?

Age differences are plausible because younger and older adults may enter a trial with different baseline memory scores, processing speeds, activity patterns and general health characteristics. In the 2023 PQQ study, the younger subgroup showed findings in selected processing-related measures at eight weeks, whereas the older subgroup showed certain memory-related findings at twelve weeks. That pattern suggests a question for future researchers: do starting cognitive characteristics influence which outcomes are most likely to change?

It does not prove that age caused the difference or that people should choose a supplementation period based on their birthday. The older subgroup contained only 33 participants, split between placebo and PQQ, and the younger subgroup contained 29. Small subgroups are especially vulnerable to unstable estimates and chance findings when several tests are performed. Larger trials that define age comparisons before enrollment would help establish whether these differences recur. Until then, age helps readers decide how similar a study population is to them, but it cannot predict an individual response.

Do Test Scores Reflect Everyday Benefits?

A better result on a cognitive test may indicate a real change in the specific ability measured, but everyday cognition involves much more than completing a computerized assessment. Remembering instructions while answering messages, concentrating during a long meeting and switching between demanding tasks all involve distractions and pressures absent from a testing room. A few points of improvement in a memory score could be meaningful, trivial or somewhere in between, depending on the scale and context.

Statistical significance describes how an observation relates to a statistical test; practical significance asks whether the difference matters in ordinary life. Published PQQ studies have reported statistically favorable differences in some cognitive domains, but they do not establish a consistent improvement in daily work performance or reliability of memory. Consumers should also pay attention to outcomes that did not improve, not just the tests highlighted in a promotional summary. The distinction is important when deciding whether a supplement's claims match the evidence or exceed it.

Measured cognitive outcome	Human research signal	What it does not establish
Composite and verbal memory	Favorable results in the 2022 and 2023 cognitive trials	Reliable improvement in everyday recall for everyone
Complex attention and cognitive flexibility	Favorable results in selected 2022 measures	Better concentration in all real-world situations
Processing and executive speed	Favorable age-subgroup findings in the 2023 trial at 8 weeks	A guaranteed onset of benefit after 8 weeks
Reaction time and motor speed	Favorable differences in selected 2022 scores	Safer driving or superior athletic performance
Stroop interference	Favorable results in the 2016 trial	Prevention or treatment of cognitive disorders

Persistent or worsening memory difficulties warrant appropriate medical assessment rather than self-treatment with a supplement. For people simply interested in maintaining everyday wellness, sleep quality, regular activity and balanced nutrition provide practical priorities while researchers continue evaluating whether PQQ produces reproducible cognitive benefits in broader populations. A clear explanation of research can be useful without asking readers to treat one promising trial as a guarantee of results.

Does PQQ Support Mitochondrial Function?

PQQ has been studied for its relationship with mitochondrial signaling, oxidation-reduction chemistry and certain metabolic markers. Small human investigations have identified changes in measures associated with mitochondrial regulation, including PGC-1α protein. However, these findings do not establish that PQQ increases the number of functioning mitochondria or improves daily energy. In a six-week exercise trial, biomarker changes occurred without additional gains in aerobic performance.

Mitochondria play an important role in how cells use nutrients to produce energy, which makes them an appealing subject for supplement marketing. But having a plausible influence on a cellular pathway is not the same as helping someone feel less tired after a long workday. The human body responds to sleep, meals, exercise, illness and many other factors at once. To understand PQQ's possible contribution, studies need to move beyond individual laboratory markers and show meaningful, reproducible changes in how people function.

How Does PQQ Affect Mitochondrial Activity?

PQQ is a redox-active compound, meaning that its chemistry involves electron-transfer reactions. Scientists have investigated whether that property affects cellular signaling and oxidative balance in experimental systems. Some laboratory studies have focused on pathways associated with mitochondrial biogenesis, the process through which cells regulate and develop their mitochondrial systems. PGC-1α is often mentioned in this research because it is involved in coordinating metabolic and mitochondrial responses to physiological demands, including those associated with exercise.

A rise in PGC-1α, however, is not a direct count of new mitochondria. Establishing improved mitochondrial function in humans would require a broader picture, potentially including measures of mitochondrial content, respiratory capacity, enzyme activity and functional outcomes. Oral absorption and metabolism also matter: a concentration that changes cell behavior in an experiment may not resemble what tissues experience after a normal supplement serving. This is why mechanistic findings are best viewed as reasons to conduct human trials, not as substitutes for them.

What Do Human Biomarker Studies Show?

Harris and colleagues conducted an early human investigation involving 10 adults, five women and five men. Participants consumed PQQ in a flavored drink during two short experiments. In the first, a single 0.2 mg/kg dose was followed by measurements over 48 hours. In the second, participants consumed 0.3 mg/kg daily, with measurements reported after approximately 76 hours. The researchers analyzed blood markers, standard clinical indices and urinary metabolites associated with metabolic pathways.

The publication reported changes in selected measures, including C-reactive protein, interleukin-6 and several urinary metabolites, while routine markers such as glucose and cholesterol were not meaningfully changed. These observations help demonstrate that PQQ exposure can be associated with measurable short-term biological responses in people. Yet a sample of 10 is too small to establish broad health effects or reliably characterize responses across different ages and lifestyles. Changes in inflammatory markers also do not demonstrate prevention of disease, and the short follow-up cannot explain what happens after months or years of use.

Does PQQ Improve Energy or Exercise Performance?

Hwang and colleagues addressed a practical question by studying 23 men who were not previously endurance trained. Participants received 20 mg of PQQ or placebo each day while completing a supervised six-week endurance exercise program. Researchers assessed aerobic performance and PGC-1α protein, along with other measures. PQQ was associated with higher PGC-1α protein levels after training, suggesting an effect on a marker involved in mitochondrial regulation.

But the performance results told a different story. The investigators found no statistically significant advantage for PQQ over placebo in aerobic performance or body composition. Peak oxygen consumption and exercise-test duration improved with training regardless of which supplement participants received. That is a useful example of the difference between seeing a biological response and demonstrating a performance benefit. It also explains why a supplement advertised through mitochondrial language should not be assumed to improve stamina, endurance or how energetic someone feels in everyday life.

Are Animal Findings Supported by Human Trials?

Animal and cell experiments have done much to generate interest in PQQ, particularly its possible interactions with mitochondrial signaling and oxidative balance. These models allow researchers to examine pathways and tissue responses in ways that may be difficult or inappropriate in healthy human volunteers. They can reveal mechanisms worth investigating, but results depend on the species, experimental conditions, dose and route of exposure. A finding in cultured cells cannot be read as a direct prediction of what happens when a person swallows a capsule or liquid supplement.

Human research provides partial biological support for studying those mechanisms, but much less support for expansive functional claims. A change in PGC-1α protein is not proof of greater mitochondrial capacity, and short-term changes in urinary metabolites do not establish improved long-term health. For a more confident conclusion, researchers would need studies combining direct mitochondrial assessments with outcomes people can understand, such as validated measures of physical function. Until then, PQQ's mitochondrial story remains scientifically interesting but incompletely translated into demonstrated human benefits.

What Do Trials Reveal About Dose and Safety?

Several cognitive PQQ trials used approximately 20–21.5 mg daily for 12 weeks, while other studies examined different amounts or shorter exposures. These are research conditions, not personal dosing recommendations. A European safety evaluation reached a conclusion for a specified PQQ disodium salt preparation under defined conditions, but that does not establish unrestricted safety for all formulas, user groups or years of continuous supplementation.

A supplement label may look similar to a published study because both mention PQQ, yet the comparison can be misleading. The actual ingredient form, amount per serving, total daily exposure and whether other active ingredients are present can differ. Even when a trial reports no adverse events, its participant population and observation period set important limits on what the result means. Reading the dose and safety evidence together is more useful than treating a familiar number on a label as a guarantee of effectiveness or tolerability.

Which PQQ Doses Were Studied?

Approximately 20 mg per day is the most familiar amount in published cognitive studies. Itoh's 2016 trial used 20 mg per day for 12 weeks; Shiojima's 2022 trial used 21.5 mg per day for the same duration; and Tamakoshi's 2023 study used 20 mg per day. The six-week exercise study also used 20 mg daily. Harris and colleagues instead tested weight-based exposures of 0.2 mg/kg once and 0.3 mg/kg daily in short experiments. A weight-based dose changes with body mass and should not be confused with a fixed retail serving.

What matters just as much as the number is the preparation being studied. Several trials specified PQQ disodium salt, while a commercial label may list a different form or use a proprietary blend. A blend containing 255 mg of several ingredients does not mean it contains 255 mg of PQQ. Consumers need an actual ingredient declaration to compare exposure with the literature. A research amount should never be interpreted as a personalized recommendation merely because it was tested in healthy volunteers.

Evidence source	Studied exposure	Observation period	What the figure means
Harris et al., 2013	0.2 mg/kg once; 0.3 mg/kg daily separately	48–76 hours	Short-term metabolic experiments, not routine-dose guidance
Itoh et al., 2016	20 mg/day	12 weeks	Specified PQQ disodium salt in a cognitive trial
Hwang et al., 2020	20 mg/day	6 weeks	Studied alongside endurance training
Shiojima et al., 2022	21.5 mg/day	12 weeks	Specified disodium salt preparation in older adults
Tamakoshi et al., 2023	20 mg/day	12 weeks	Specified disodium salt in adults ages 20–65
EFSA opinion, 2017	Maximum proposed intake: 20 mg/day	Safety assessment, not a benefit trial	Applied to a defined ingredient and intended conditions of use

How Long Did Participants Take PQQ?

Trial duration follows the research question. Investigators may need only days to look for short-term changes in certain metabolites, whereas cognitive studies commonly assess participants over twelve weeks. The 2023 cognitive study took measurements at baseline, eight weeks and twelve weeks, enabling researchers to describe when selected differences appeared within that particular group. This schedule does not establish that all users should expect to notice changes at eight or twelve weeks, or that a shorter trial period would be ineffective.

Longer observation introduces questions that most published cognitive studies cannot yet answer. Do measured differences persist after many months, do they remain noticeable to participants, and does prolonged exposure change the safety picture? Some human safety-related evidence reviewed by European regulators included studies lasting up to 24 weeks, but that remains different from systematic observation over years. Anyone comparing supplements should distinguish a trial's follow-up schedule from a recommendation for continuous personal use, especially when the product combines several active ingredients.

What Side Effects Were Reported?

The published PQQ cognitive trials have generally reported few safety concerns over their studied periods. The 2022 trial recorded no adverse events among its participants, and the 2016 publication described no abnormal findings on the safety measures assessed. Such observations provide some reassurance about the particular material and population studied, but a small trial cannot detect every possible reaction. Rare effects, interactions or issues that develop slowly may not appear in a group of a few dozen healthy volunteers.

The European Food Safety Authority (EFSA) assessed a specified PQQ disodium salt ingredient in 2017. Its opinion considered a proposed maximum intake of 20 mg daily in supplements intended for healthy adults, excluding pregnant and breastfeeding women and children. EFSA concluded that the ingredient was safe under the evaluated conditions, while also identifying limitations in the available human safety studies, including incomplete assessment of kidney function. A safety evaluation for one characterized preparation does not amount to approval of all PQQ products or evidence that higher amounts and longer exposure are suitable for everyone.

Is Long-Term PQQ Safety Established?

Current human findings do not establish comprehensive safety for indefinite PQQ use across every population. Several well-known cognitive trials lasted twelve weeks, and the broader human safety literature considered by EFSA included studies running from days to a maximum of 24 weeks. These periods can reveal some short-term tolerability issues but are not designed to answer all questions about years of daily exposure. The number and diversity of participants also matter when trying to detect uncommon adverse events.

Personal circumstances make the question more complicated. Pregnant or breastfeeding individuals, people managing health conditions and those taking medications may not resemble the healthy volunteers enrolled in PQQ trials. Multiple products can also overlap: a person could take standalone PQQ and a second blend containing PQQ without knowing the combined quantity. Reading the current Supplement Facts label, avoiding assumptions about proprietary blends and discussing relevant health circumstances with a qualified professional are more sensible than treating the absence of reported problems in small studies as a zero-risk guarantee.

How Strong Is the Human Evidence for PQQ?

The human evidence for PQQ is promising in selected cognitive outcomes but remains limited overall. Randomized trials provide useful signals, while metabolic and exercise studies demonstrate biological activity without consistently showing functional improvements. Small samples, relatively short follow-up, varied measurements and limited independent replication restrict confidence in broad claims. Better-powered studies measuring meaningful everyday outcomes are still needed before the findings can be generalized.

Good scientific evidence is not simply a collection of positive headlines. It is a pattern of results that appears across appropriately designed studies, with findings large enough to matter and populations similar enough to the people who may use the product. PQQ research is valuable because some investigators have applied controlled clinical methods, but there are still unanswered questions about which outcomes are reproducible, how much any change matters and whether the findings extend beyond the particular preparations examined.

Are the Clinical Trials Large Enough?

The most frequently cited PQQ trials are useful early studies rather than large confirmatory investigations. The 2013 metabolism experiment included ten adults; the 2016 cognitive trial included 41; the 2022 cognitive study randomized 64 and retained 58 completers; and the 2023 cognitive study included 62. The exercise investigation involved 23 men. Each of these participant groups offers information about a specific research question, but none is large enough by itself to establish a reliable benefit across adults of different ages, backgrounds and health circumstances.

Small studies face two kinds of difficulty. They may miss a real but modest effect, and they may estimate an observed effect with considerable uncertainty. Results can also shift when one or two participants differ substantially from the rest of the group. There is no universal minimum sample size that guarantees quality, because the appropriate number depends on the outcome and expected effect. Larger, independently replicated trials could clarify whether the promising cognitive findings are stable and whether their actual magnitude justifies consumer expectations.

What Are the Main Research Limitations?

PQQ studies have often used different participant populations, tests and formulations, making straightforward comparison difficult. An older-adult cognition study cannot be pooled casually with a young-adult exercise study, and a change in a biomarker cannot be counted as equivalent to a benefit in everyday functioning. Some trials also examine many cognitive measures at once, creating a need for careful statistical interpretation. If several outcomes are tested, isolated favorable results may occur even when the broader pattern is less persuasive.

Commercial relationships deserve transparent consideration as well. Some publications include affiliations or funding connected to PQQ suppliers, and this information should be disclosed alongside the results. Industry involvement does not invalidate research, but successful replication by independent groups would increase confidence. Finally, most studies do not follow people long enough to resolve the durability of benefits or long-term tolerability. Together, these limitations explain why the literature supports continued research without justifying sweeping claims that PQQ reliably enhances memory, physical energy or healthy aging.

Can PQQ Trial Results Apply to Supplement Blends?

A study testing standalone PQQ cannot automatically prove the effects of a multi-ingredient formula. Even when a blend includes an ingredient named in a clinical paper, the amount, chemical form, delivery format and combination of other substances may differ. A 20 mg PQQ disodium salt study does not establish that a liquid product with an undisclosed PQQ amount provides the same exposure or produces the same cognitive changes. The relationship between an ingredient study and a finished product must be shown, not assumed.

This distinction matters for NAD-related formulas containing several supporting ingredients. AirVigor includes PQQ among supporting ingredients in certain NAD-related liquid products, but the individual PQQ amount and chemical form have not been confirmed in the available brand fact documentation. Those products can be discussed in terms of their actual format, listed ingredients and intended daily routine; published standalone PQQ trials should remain background education rather than proof of finished-product efficacy. A clear label and realistic expectations are more valuable to consumers than a clinical claim that exceeds the available evidence.

Is PQQ Worth Considering?

For adults following research on cognition and cellular wellness, PQQ is a legitimate subject of interest. Small controlled studies have reported favorable changes in certain cognitive measures, and human metabolism research suggests biological activity worth exploring further. But there is not enough evidence to say that PQQ is necessary for healthy adults, that it reliably makes people more energetic or that everyone will experience a meaningful cognitive benefit. A supplement decision should reflect the gap between an interesting research signal and a predictable personal result.

The practical approach is to check the specific ingredient, read the serving information carefully and consider the whole formula rather than focusing on one fashionable compound. Sleep, a varied diet, physical activity and suitable medical care remain important foundations for cognitive and physical well-being. If a product contains PQQ, the most useful question is not whether the ingredient has ever appeared in a positive study, but whether the evidence truly relates to that product and to the result someone expects from it.

Final Thoughts

PQQ has been tested in humans, and several randomized cognitive studies have reported encouraging differences in selected memory, attention and processing measures. That makes it more than an ingredient supported solely by cell experiments or animal work. Yet the research has practical limits: trials have usually involved small groups, outcomes vary, and findings in laboratory markers have not consistently translated into improved physical performance. Short-term safety observations are useful, but they do not answer every question about extended use or differing supplement formulations.

For consumers, the most useful result of reading clinical research is a clearer sense of what is known and what remains uncertain. A product that lists PQQ is not automatically equivalent to the preparation studied in a trial, and a positive test score is not a promise of better everyday memory. Choosing nutrition products becomes simpler when ingredient amounts are clear, claims stay close to the evidence and expectations reflect the realities of daily life rather than the strongest wording on a product page.

Frequently Asked Questions

Has PQQ been tested in human clinical trials?

Yes. PQQ has been studied in randomized, double-blind, placebo-controlled human trials, including investigations of cognitive function published in 2016, 2022 and 2023. Additional studies have examined short-term metabolism and exercise-related biomarkers. These are genuine human investigations, but most recruited fewer than 100 participants, and they tested different outcomes. Their existence establishes that human research has been conducted; it does not mean that every proposed health benefit has been confirmed or that the findings apply equally to all PQQ products.

Does PQQ improve memory and concentration?

Some studies reported favorable results in selected cognitive tests, including composite memory, verbal memory and measures of attention or processing. Trials using approximately 20–21.5 mg daily for twelve weeks are often cited in this context. However, results vary by outcome and participant group, and the research has not firmly established noticeable improvements in everyday memory or concentration. It is more accurate to say that early clinical evidence is encouraging in certain measured domains than to promise that taking PQQ will make someone mentally sharper.

How much PQQ did human studies use?

Several controlled cognitive studies used about 20 mg daily, while one 2022 trial used 21.5 mg daily of a specified PQQ disodium salt preparation. The 2013 metabolism study used weight-based amounts in short experiments, so its exposures were structured differently. These figures describe study protocols, not recommendations for an individual. Ingredient form, amount per serving, other supplement use and personal health circumstances matter. Consumers should not assume that a formula containing PQQ delivers a research-equivalent amount unless that information is clearly available.

How long does PQQ take to work in human studies?

The answer depends on what researchers measured. Cognitive studies commonly evaluated participants after twelve weeks, and a 2023 trial also reported selected age-subgroup findings at eight weeks. Metabolic experiments measured changes within days, but those outcomes were biomarkers rather than a feeling of improved concentration or energy. Study measurement times are not guaranteed personal response times. Current research cannot reliably predict when someone would notice a benefit, how large it would be, or whether it would persist after the study period.

Does PQQ increase mitochondria or boost energy?

Laboratory work and small human studies have investigated PQQ's relationship with mitochondrial signaling. In a six-week exercise trial, participants receiving PQQ showed increased levels of PGC-1α, a protein associated with mitochondrial regulation. However, they did not demonstrate superior aerobic performance compared with placebo. That distinction is important because an effect on a molecular marker does not prove more functioning mitochondria or greater everyday energy. At present, human evidence is insufficient to treat PQQ as a reliably demonstrated energy or endurance enhancer.

Is PQQ safe to take every day?

Short-term clinical studies have generally reported limited safety concerns under the conditions tested, and a 2017 EFSA opinion concluded that a specified PQQ disodium salt preparation was safe at the proposed 20 mg daily intake for healthy adults under evaluated conditions. That assessment did not establish unrestricted safety for all ingredient forms or users, and it excluded children and pregnant or breastfeeding women from the intended population. People taking medication, managing a health condition or combining supplements should consider their individual circumstances with an appropriate healthcare professional.

Is PQQ the same as CoQ10 or NAD+?

No. PQQ, coenzyme Q10 (CoQ10) and nicotinamide adenine dinucleotide (NAD+) are different compounds, even though marketing often places them in similar conversations about cellular wellness. Research involving one cannot establish the effects of another, and a combination product cannot claim the benefits of each ingredient solely because separate studies exist. The practical questions remain the same: what ingredient is present, how much is provided, what exact preparation was studied, and whether controlled human research supports the specific outcome being discussed.

Selected Research and Regulatory Sources

Harris CB, et al. (2013). Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects. Journal of Nutritional Biochemistry. https://pubmed.ncbi.nlm.nih.gov/24231099/

Itoh Y, et al. (2016). Effect of the Antioxidant Supplement Pyrroloquinoline Quinone Disodium Salt (BioPQQ) on Cognitive Functions. Advances in Experimental Medicine and Biology. https://pubmed.ncbi.nlm.nih.gov/26782228/

Hwang PS, et al. (2020; online publication in 2019). Effects of Pyrroloquinoline Quinone Supplementation on Aerobic Exercise Performance and Indices of Mitochondrial Biogenesis in Untrained Men. Journal of the American College of Nutrition. https://pubmed.ncbi.nlm.nih.gov/31860387/

Shiojima Y, et al. (2022; online publication in 2021). Effect of Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. Journal of the American Nutrition Association. https://pubmed.ncbi.nlm.nih.gov/34415830/

Tamakoshi M, et al. (2023). Pyrroloquinoline quinone disodium salt improves brain function in both younger and older adults. Food & Function. https://pubmed.ncbi.nlm.nih.gov/36807425/

European Food Safety Authority (2017). Safety of pyrroloquinoline quinone disodium salt as a novel food pursuant to Regulation (EC) No 258/97. EFSA Journal. https://doi.org/10.2903/j.efsa.2017.5058

U.S. Food and Drug Administration. Structure/Function Claims. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/structurefunction-claims

Health Information Notice: This article is provided for general educational purposes. It summarizes published research on an ingredient rather than demonstrating that any particular finished supplement has the same effects. It is not medical advice and does not establish that PQQ can diagnose, treat, cure or prevent disease. People with health concerns, those taking medicines and anyone who is pregnant or breastfeeding should seek individualized advice from a qualified healthcare professional before considering supplements.